Skip to main
EXEL
EXEL logo

Exelixis (EXEL) Stock Forecast & Price Target

Exelixis (EXEL) Analyst Ratings

Based on 28 analyst ratings
Buy
Strong Buy 39%
Buy 25%
Hold 36%
Sell 0%
Strong Sell 0%

Bulls say

Exelixis Inc. has demonstrated robust quarter-over-quarter growth in its Cabometyx franchise, achieving a reported revenue of $515.2 million for the fourth quarter of fiscal year 2024, representing a 20% year-over-year increase. The company's strategic positioning in the oncology market, particularly its anticipated use in 30% of the second-line neuroendocrine tumor patient population, supports a strong potential for revenue expansion, with analysts estimating U.S. peak sales of approximately $290 million. Furthermore, the combination of Cabometyx with Opdivo has established it as the most prescribed tyrosine kinase inhibitor in renal cell carcinoma, enhancing Exelixis's growth outlook amidst favorable market conditions.

Bears say

Exelixis Inc faces significant challenges that negatively impact its stock outlook, primarily stemming from expectations regarding the market share of cabozantinib (Cabo) in key indications, which are projected to be much lower than previously anticipated in the first-line renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC) settings. The firm is exposed to multiple risks, including potential R&D and regulatory setbacks, competition from new therapies, and diminishing sales for its current products, particularly cabozantinib, which may further diminish its revenue streams in the face of generic erosion. Additionally, concerns regarding the efficacy and tolerability of its pipeline candidate, zanzalintinib, along with the potential for long-term dilution risk, contribute to an uncertain financial outlook for Exelixis.

Exelixis (EXEL) has been analyzed by 28 analysts, with a consensus rating of Buy. 39% of analysts recommend a Strong Buy, 25% recommend Buy, 36% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Exelixis and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Exelixis (EXEL) Forecast

Analysts have given Exelixis (EXEL) a Buy based on their latest research and market trends.

According to 28 analysts, Exelixis (EXEL) has a Buy consensus rating as of Jul 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35.52, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35.52, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Exelixis (EXEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.